Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 13/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6576436 | 0.91 | EPHX1 (0.53) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL28481312 | 0.85 | EPHX1 (0.52) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL29160583 | 0.81 | EPHX1 (0.58) | EPHX1ACHENAAA | |
| SCHEMBL1136659 | 0.81 | SMN1; SMN2 (0.45) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL6269354 | 0.79 | ACHE (0.68) | EPHX1ACHE | |
| SCHEMBL4632318 | 0.78 | EPHX1 (0.53) | EPHX1ACHENAAA | |
| SCHEMBL15397844 | 0.78 | ALDH1A1 (0.42) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL29991047 | 0.77 | ACHE (0.71) | EPHX1ACHE | |
| SCHEMBL7677452 | 0.77 | ACHE (0.71) | EPHX1ACHE | |
| SCHEMBL6950987 | 0.77 | ACHE (0.71) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182783-A1 | Growth Hormone Conjugates | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182783-A1 | Growth Hormone Conjugates | GHRHR, GHSR, GHITM | EPHX1 3058/4885ACHE 4641/4885ALDH1A1 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.